Compare · ABT vs IRD
ABT vs IRD
Side-by-side comparison of Abbott Laboratories (ABT) and Opus Genetics Inc. (IRD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and IRD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 537.6x IRD ($336.9M).
- ABT has been more active in the news (13 items in the past 4 weeks vs 5 for IRD).
- ABT has more recent analyst coverage (25 ratings vs 14 for IRD).
- Company
- Abbott Laboratories
- Opus Genetics Inc.
- Price
- -
- -
- Market cap
- $181.14B
- $336.9M
- 1M return
- -
- -27.01%
- 1Y return
- -
- +104.79%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 13
- 5
- Recent ratings
- 25
- 14
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest IRD
- Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
- SEC Form 8-K filed by Opus Genetics Inc.
- Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
- Opus Genetics to Present at the Chardan Annual Healthcare Conference
- Director Foundation Fighting Blindness Retinal Degeneration Fund sold $2,755,981 worth of shares (556,000 units at $4.96) (SEC Form 4)
- Chief Executive Officer Magrath George exercised 392,157 shares at a strike of $1.15 and covered exercise/tax liability with 75,541 shares, increasing direct ownership by 18% to 2,048,485 units (SEC Form 4)
- Opus Genetics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Four Biotech Stories Heating Up Right Now
- Opus Genetics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits